Dupixent vs Stelara
Side-by-side cost comparison based on Medicare Part D data
Dupixent
Dupilumab
Manufactured by Regeneron/Sanofi
Stelara
Ustekinumab
Manufactured by Janssen
Dupixent costs 64% less per claim than Stelara ($2,819.00 vs $7,763.00).
Cost Per Claim
Medicare Spending
Beneficiaries
Annual Cost Per Patient
Full Comparison
| Metric | Dupixent | Stelara |
|---|---|---|
| Avg Cost Per Claim | $2,819.00 | $7,763.00 |
| Total Medicare Spending | $4.4B | $5.6B |
| Total Beneficiaries | 245,000 | 114,000 |
| Total Claims | 1,560,000 | 720,000 |
| Annual Cost/Patient | $17,951.00 | $49,026.00 |
| Year-over-Year Change | +35.2% | +6.3% |
| Generic Available | No | Yes |
| Patent Expiration | Mar 28, 2031 | Jan 31, 2023 |
| Manufacturer | Regeneron/Sanofi | Janssen |
| Condition | Autoimmune Diseases | Autoimmune Diseases |
| Generic Name | Dupilumab | Ustekinumab |
Dupixent vs Stelara: What the Data Shows
Dupixent (Dupilumab) and Stelara (Ustekinumab) are both used to treat autoimmune diseases. Based on Medicare Part D data, Dupixent costs $2,819.00 per claim, which is 64% less than Stelara at $7,763.00 per claim.
Medicare spent $4.4B on Dupixent and $5.6B on Stelara. In terms of patient reach, Dupixent serves more beneficiaries (245,000 vs 114,000).
Year-over-year spending changed +35.2% for Dupixent and +6.3% for Stelara. Dupixent saw significant spending growth, suggesting increased utilization or price increases.
Stelara has a generic available, while Dupixent remains brand-only until its patent expires Mar 28, 2031.
Frequently Asked Questions
Dupixent is cheaper at $2,819.00 per claim, compared to $7,763.00 for Stelara. That makes Dupixent about 64% less expensive per claim based on Medicare Part D data.
Yes, both Dupixent and Stelara are used to treat autoimmune diseases. Your doctor can help determine which medication is more appropriate for your specific situation.
Stelara has a generic version (Ustekinumab) available, which is typically much cheaper. Dupixent is currently brand-only, with patent expiring Mar 28, 2031.
Medicare Part D spent $4.4B on Dupixent covering 245,000 beneficiaries, and $5.6B on Stelara covering 114,000 beneficiaries.
Explore Further
Cost data reflects Medicare Part D spending and may not represent retail pharmacy prices. Average cost per claim represents the total drug cost (not patient out-of-pocket) divided by total claims. This comparison is informational only and should not replace medical advice.